TSLP and asthma: In a phase 2 trial of patients with uncontrolled moderate-to-severe asthma randomized to different doses of tezepelumab versus placebo, anti-TSLP therapy reduced asthma exacerbations regardless of high or low blood eosinophil subgroups [27].